Australian University Rankings Guide

Birth Defects Research Part A: Clinical and Molecular Teratology (ERA Journal)

Birth Defects Research Part A: Clinical and Molecular Teratology is an ERA accredited research journal used as part of the evaluation of the ERA research rankings.

Birth Defects Research Part A: Clinical and Molecular Teratology issns are issn1: 1542-0752 issn2: 1542-0760.

The fields covered by Birth Defects Research Part A: Clinical and Molecular Teratology as part of the evaluation of Australian university research excellence are:

Paediatrics and Reproductive Medicine Research Rankings (Sub-Field)

Public Health and Health Services Research Rankings (Sub-Field)

Other ERA-accredited journals supporting the evaluation of the Paediatrics and Reproductive Medicine field include:

- Academic Pediatrics
- Clinical Obstetrics and Gynecology
- Current Topics in Developmental Biology
- Journal of Paediatrics Obstetrics and Gynaecology (Hong Kong Edition)
- Journal of Perinatal Medicine: official journal of the World Association of Perinatal Medicine
- Obstetrics and Gynecology
- Pediatric Dermatology
- Pediatric Endocrinology Reviews
- Pediatric Health Medicine and Therapeutics
- Pediatric Pulmonology
- Pediatric Radiology: roentgenology nuclear medicine ultrasonics CT MRI
- Placenta
- Spermatogenesis
- The European Journal of Contraception and Reproductive Health Care
- The Prostate


ERA Research Rankings Submenu


- ERA 2018 Outcomes Research Rankings List

- ERA 2018 Research Rankings Analysis

- ERA 2018 Individual University Outcomes List

- ERA List of Research Fields Rankings

- ERA Journal Rankings 2018 List



Latest News and Updates:


- Top 10 Best Australian Universities

- Gender Balance Male-Female Ratio

- ERA 2018 Outcomes Research Rankings List

- University Bachelor Degree Completion Rates

- QS Employability Rankings Australian Universities

- ARWU World Rankings of Australian Universities

- Group of Eight (go8) World Rankings

Share This Page

  • Share on Facebook1
  • Share on Twitter2
  • Share on Linkedin3
  • Share on Reddit4